Clinical Guide · July 2026
Vaginal Dryness Not Improving on HRT? What to Check Next
Last verified: · By The HRT Index Editorial Team · Editorial research; educational only — not medical advice
If your vaginal dryness is not improving on HRT, here’s the first thing to know: it does not automaticallymean your treatment failed or that your dose is too low. Systemic HRT — the pill, patch, gel, or spray — can improve vaginal symptoms, but it doesn’t always fully relieve them. When your whole-body symptoms get better and the dryness stays, the usual next conversation isn’t a bigger dose. It’s whether to add a small amount of low-dose local vaginal estrogen, aimed directly at the tissue.
That local treatment can take up to 3 months to work fully, so judging it after only a few days or weeks is often too soon.
This page is for you if:you’re already on systemic HRT or a prescribed vaginal treatment and you still have dryness, burning, painful sex, tearing, or urinary symptoms.
Please don’t use this page to explain away:new or unexplained bleeding after menopause, repeated bleeding after sex, unusual discharge or odor, visible sores or skin changes, or pain that’s severe or getting worse. Those need to be checked by a clinician — not treated with more hormones.
7 checks before you change anything
Run through these before you ask for a bigger dose or give up. They’re the same things a good clinician will want to know.
- 1
Your exact product and route — is it systemic (pill, patch, gel, spray) or local (vaginal cream, tablet, insert, ring)?
- 2
Your start date — and any date it was changed or switched at the pharmacy.
- 3
How you've used it — exactly as prescribed, or with missed doses?
- 4
What your other menopause symptoms did — did hot flashes, sleep, or mood improve while dryness stayed?
- 5
Whether the product itself irritates you — burning or itching that starts right after you use it.
- 6
Whether there are red-flag symptoms — bleeding, unusual discharge, skin changes, urinary symptoms, or worsening pain.
- 7
Whether your next step is a medication review or an in-person exam.
Quick answer: what’s happening and what to do
| What’s going on | Best question to ask | Likely next step |
|---|---|---|
| A patch, pill, or gel helped hot flashes or sleep, but dryness stayed | "Could low-dose local vaginal estrogen be right for me?" | A routine HRT review — if you have no red flags |
| You started a vaginal treatment recently | "Am I using the right product and schedule, and when do we reassess?" | Keep going as prescribed — full benefit can take up to 3 months |
| A vaginal treatment has had a fair trial with little change | "Does the product or the diagnosis need a second look?" | A clinician review — not raising the dose on your own |
| New or unexplained bleeding, odd discharge, skin changes, or worsening pain | "Do I need an exam or testing?" | See a clinician in person |
What we actually verified
We checked the 2025 genitourinary syndrome of menopause (GSM) guideline from the American Urological Association and its partner societies (AUA/SUFU/AUGS), current ACOG guidance (including its 2021 consensus on urogenital symptoms after breast cancer and its April 2026 update on evaluating postmenopausal bleeding), The Menopause Society, the FDA’s February 12, 2026 labeling changes, and current FDA prescribing information on DailyMed (Estring, Femring, Duavee, Intrarosa, Osphena).
The right online HRT provider isn’t the same for every woman — use The HRT Index’s Find My HRT Path tool to match your situation.
Find my HRT path →Why is vaginal dryness not improving on HRT?
Vaginal dryness can continue on HRT for a few reasons: systemic HRT may not fully relieve local symptoms, the treatment may not have had enough time, it may not be used as prescribed, or another condition may be contributing. The 2025 AUA/SUFU/AUGS guideline advises ruling out other causes and coexisting conditions rather than assuming every leftover symptom is simply “low estrogen.”
Menopause hormone therapy comes in two jobs. Systemic HRT(a patch, pill, gel, or spray) circulates through your whole bloodstream. It’s used mainly for hot flashes, night sweats, and sleep — and it can improve vaginal symptoms too. Local vaginal estrogen (a cream, tablet, insert, or low-dose ring) is designed for the vaginal and urinary symptoms of menopause, with much lower systemic exposure than systemic estrogen.
The menopause condition behind that dryness has a name: genitourinary syndrome of menopause (GSM), the current term for the thinning, drying, and irritation of vaginal and urinary tissue that can come with lower estrogen. GSM sometimes needs its own treatment even when systemic HRT is helping elsewhere.
Older published reviews reported residual urogenital symptoms in roughly 10% to 25% of women using systemic hormone therapy. Across studies of low-dose vaginal estrogen for GSM, about 60% to 80% of participants reported subjective improvement. Yet uptake is low: a 2025 Medicare cohort found that only 9.0% of women aged 66 or older with a GSM-related diagnosis had filled a vaginal-estrogen prescription.
Persistent Dryness on HRT: Route-and-Response Matrix
Version 1.0 · Last verified · A discussion aid, not a diagnostic tool.
| What you’re noticing | What it may mean | What to verify | Safest next conversation | Timing |
|---|---|---|---|---|
| A patch, pill, or gel improved hot flashes or sleep, but dryness remains | Systemic HRT can help elsewhere without fully relieving local symptoms | Your exact systemic product, start date, how consistently you take it | Ask whether your symptoms fit GSM and whether local treatment should be added | Routine review if no red flags |
| You started systemic HRT only recently | It may not have hit its planned review point — and systemic HRT can still leave local symptoms behind | Start date, dose changes, missed doses, what did improve | Ask for a defined review date instead of waiting indefinitely | Earlier review if severe; otherwise your prescriber's checkpoint |
| You started vaginal estrogen only recently | Improvement can begin in weeks; full benefit can take up to 3 months | Exact product, the schedule you were given, whether it irritates | Confirm you're using it correctly and set a reassessment date | Continue as prescribed; review sooner if worse |
| Vaginal treatment has had a fair trial with little change | The product, schedule, diagnosis, or another condition may need a second look | Product, route, use pattern, any symptom besides dryness | Ask for a formulation and diagnosis review — not an automatic dose increase | Book a clinician review |
| A product makes burning or itching worse | Irritation, an ingredient reaction, infection, or another condition may be involved | When it happens, other products you use, discharge, odor, skin changes | Contact your prescriber; ask whether an exam or test is needed | Prompt review if it persists |
| Unusual discharge or odor | Vaginitis or another cause may need testing | Color, odor, itching, pain, urinary symptoms, recent products | Get assessed instead of assuming it's low estrogen | Timely in-person review |
| Dryness improves a little, but tightness, tearing, or pain continues | Pelvic-floor tension, a vulvar skin condition, or another pain issue may coexist | Where the pain is, visible skin changes, tearing, entry vs deep pain | Ask about an exam and whether pelvic-floor or vulvar assessment fits | In-person assessment if it persists |
| New or unexplained postmenopausal bleeding, or repeated bleeding after sex | Dry tissue can bleed — but new or unexplained bleeding is evaluated, not assumed to be dryness | Amount, pattern, whether it's expected withdrawal bleeding on your regimen | Report it promptly | Prompt assessment |
| Ongoing urgency, frequency, or repeated UTI-like symptoms | GSM can include urinary symptoms — but an active infection may need testing | Urine testing, past cultures, antibiotic history, timing | Ask whether infection was ruled out and whether GSM is contributing | Review during symptoms |
| You've had breast cancer, or take tamoxifen or an aromatase inhibitor | Your options need an individual risk-benefit talk | Cancer type, current therapy, oncology advice, what you've tried | Coordinate gynecology and oncology — no blanket online answer | Clinician-led decision before any hormone change |
The “what it may mean” and “safest next conversation” columns are The HRT Index’s editorial care-routing judgment, based on the sourced guidance cited on this page. They help you organize a conversation. They do not diagnose the cause of any one symptom.
On this page, a “fair trial”means using the exact prescribed product and schedule through your prescriber’s planned review point — often up to three months for vaginal estrogen — unless your symptoms get worse or a red flag appears sooner.
Does this sound like your situation?Use The HRT Index’s Find My HRT Path tool to see which path fits — more time, a treatment review, or an in-person exam — and whether online care is the right place to start.
Find my HRT path →Does persistent dryness mean my HRT dose is too low?
Not necessarily — and this is worth getting right before you ask for more. Dryness alone doesn’t prove your systemic estrogen dose is too low. Your route, timing, how consistently you use it, whether your other symptoms improved, local-treatment options, and other possible causes all matter before changing a whole-body dose.
Here’s a clue that cuts through the guessing: look at what your other menopause symptoms did.
- •Did your hot flashes settle down?
- •Did night sweats ease?
- •Is your sleep better?
- •Is dryness the only thing still hanging on?
If your whole-body symptoms improved and dryness is the lone holdout, that pattern is consistent with persistent GSM. It supports discussing local treatment or another cause — it does not prove your systemic dose is too low.
There’s a measurable reason to reach for a local tool instead of a bigger systemic dose. Low-dose vaginal estrogen is designed to work at the tissue with much lower systemic exposure. The low-dose vaginal ring Estring is a good example: after an initial short peak, its FDA label reports mean steady-state blood estradiol of about 7.0 to 8.1 pg/mL, and after the first eight hours, systemic levels were within the range seen in untreated women. More whole-body estrogen isn’t a stronger version of the same tool. It’s a different tool for a different job.
Please don’t self-adjust
Don’t raise a systemic dose, add extra vaginal medicine, or combine products based on an online checklist — including this one. The point of sorting this out is to walk into your appointment with the full picture.
How long should HRT take to improve vaginal dryness?
Some women notice local treatment helping within a few weeks, but vaginal estrogen can take up to 3 monthsto work fully. Systemic HRT also needs a defined review window. That timeline is a reason to be patient — not a reason to sit on new bleeding, unusual discharge, or pain that’s getting worse.
Systemic HRT.Whole-body symptoms often shift first. Hot flashes and sleep may improve before anything changes below — or your local symptoms may persist even though systemic HRT can improve GSM. A three-month review point is a good planning marker, not a promise that dryness will be gone by then.
Local vaginal estrogen.Early improvement can begin in a couple of weeks. Full benefit can take up to three months. Schedules differ by product — follow the exact label and prescription for the product you were given. If you stopped after the starting phase, or skipped maintenance doses, the treatment may simply not have had a fair trial.
Moisturizers and lubricants do different jobs — don’t confuse them. A lubricant reduces friction during sex and works right away, but briefly. A vaginal moisturizeris used regularly for day-to-day comfort. Neither restores estrogen, and neither tells you what’s causing your symptoms.
| Treatment or support | What you may notice | The review question to ask |
|---|---|---|
| Systemic patch, pill, gel, or spray | Other menopause symptoms may improve first — or local symptoms may persist | "Has this had a fair trial, and are my local symptoms being treated separately?" |
| Prescribed local vaginal estrogen | Some improvement in weeks; full benefit up to 3 months | "What date do we reassess, and what counts as not enough improvement?" |
| Lubricant | Immediate but temporary comfort during sex | "Is sex still painful even with plenty of lubricant?" |
| Vaginal moisturizer | Ongoing comfort with regular use | "Is this enough, or do I need a prescription or a diagnosis review?" |
If you’ve truly given it a fair trial and nothing has budged, that’s not a signal to double down alone — it’s a signal to get a second look.
Can I add vaginal estrogen to the HRT I’m already on?
Often, yes — adding a recommended low-dose local vaginal estrogen is a common option when local symptoms persist on systemic HRT. The two routes do different jobs, so using one doesn’t make the other pointless. But the exact product, your systemic regimen, and your symptom pattern all matter, so this is a prescriber conversation — not a self-serve add-on.
Major guidance supports it. The 2025 AUA/SUFU/AUGS GSM guideline says women already on systemic hormone therapy who still have genitourinary symptoms should be offeredlow-dose vaginal estrogen (or vaginal DHEA). And here’s a detail that eases a common worry: because low-dose local estrogen produces much lower systemic exposure, adding it generally does notrequire adding a progestogen. Two limits on that: it doesn’t apply to systemicvaginal products like Femring, and it doesn’t replace the progestogen plan your systemic HRT already requires. Confirm your own case with your prescriber.
One important exception: Duavee
If your systemic treatment is Duavee (conjugated estrogens plus bazedoxifene), its current FDA label says you should not take additional estrogens. So adding vaginal estrogen means reviewing your whole regimen — not the general “often yes.”
Two things worth confirming about your product
FDA-approved low-dose vaginal estrogen exists as creams, tablets or inserts, and a low-dose ring. Your clinician picks the form that fits your symptoms and routine. For a fuller side-by-side, see our guides on using vaginal estrogen with systemic HRT and vaginal estrogen vs systemic estrogen.
Estring and Femring are not the same thing
Both are vaginal rings. They’re worlds apart.
Estring — LOCAL
Low-dose vaginal estradiol ring. After an initial short peak, its FDA label reports mean steady-state blood estradiol of about 7.0 to 8.1 pg/mL. Low systemic absorption. Used for local GSM symptoms only.
Femring — SYSTEMIC
Delivers systemic estradiol. FDA label reports average blood estradiol of about 40.6 pg/mL and 76 pg/mLfor its two strengths — enough to treat hot flashes. Women with a uterus generally need a progestogen with it.
Always confirm which ring you actually have before acting on advice about “vaginal estrogen.”
The Boxed-Warning Reset: what changed in 2026
For years, low-dose vaginal estrogen carried the same strong “boxed warning” as systemic hormone therapy — mentioning risks like heart disease, breast cancer, and dementia. That language was largely drawn from studies of systemic estrogen at systemic doses. Menopause specialists argued it overstated the risk for low-dose local products and pushed women away from a treatment that helps.
On February 12, 2026, the FDA approved updated prescribing information for the first six menopause-hormone products: Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva.Estring — the low-dose vaginal ring — is the only vaginal estrogen on that first list.
Two honest guardrails
- This does notmake vaginal estrogen “risk-free.” Every medicine has trade-offs, and your history still matters.
- As of mid-July 2026, other vaginal products — Vagifem, Yuvafem, Imvexxy, Estrace vaginal cream, and Premarin vaginal cream — are not yet on the FDA’s updated list. Check your product’s current label on DailyMed or ask your pharmacist.
FDA-approved and compounded are not the same
You may see “compounded” or “bioidentical” vaginal estrogen marketed online. Compounded products are mixed by a pharmacy and are not FDA-approved— they aren’t reviewed by the FDA for safety, effectiveness, dose accuracy, or quality the way approved products are. ACOG recommends against routine compounded menopausal hormone therapy when an FDA-approved option meets the need.
Not sure where your situation fits?Get matched to the care route that fits your symptoms, state, and preferences — and see whether an in-person visit should come first.
Find my HRT path →I’m already using vaginal estrogen and it’s still not working — now what?
If you’re already on vaginal estrogen and still dry, start by verifying four things: the exact product, how long you’ve used it, whether you’re using it as prescribed, and whether it irritates you. Little or no improvement by your planned review point deserves a real reassessment of the product, the diagnosis, and any coexisting condition — not an automatic decision to use more on your own.
- 1
Confirm exactly what you're using
Write down the brand or generic name, the form (cream, tablet, insert, or ring), whether it's FDA-approved or compounded, your prescription instructions, and your start date. If you had a refill, check whether the pharmacy substituted a different product or form — and record that switch date, because the formulation and instructions may differ.
- 2
Confirm the schedule — without copying one from an article
Products differ. Read your label, ask your prescriber, and don't borrow a schedule from a different product.
- 3
Check whether the product itself is the problem
Ask yourself: Does burning start right after you apply it? Is the irritation outside, inside, or both? Did symptoms begin after a new cleanser, lubricant, pad, detergent, or wipe? Is there discharge or odor? Don't stop a prescription on your own — but do tell your prescriber if it's making things worse.
- 4
Reassess whether dryness is even the main symptom
"Dryness" is often a stand-in for a mix: burning, itching, entry pain, deep pain, tightness, tearing, bleeding, urinary urgency, discharge. The exact mix points in very different directions.
- 5
Ask whether the diagnosis or formulation needs review
A clinician might discuss a different FDA-approved form, testing for infection or a skin condition, a pelvic-floor assessment, a non-hormonal add-on, or a different prescription option — and, if your other menopause symptoms are also uncontrolled, a broader HRT review.
Bring this to your appointment
| Bring | Why it helps |
|---|---|
| A photo of the product box and prescription label | Prevents route or product mix-ups (like Estring vs Femring) |
| Your start date and any missed doses | Shows whether the trial was actually fair |
| A simple symptom timeline | Shows what improved and what got worse |
| A list of cleansers, moisturizers, lubricants, pads, and detergents | Helps spot irritation |
| Any bleeding, discharge, urinary, or skin symptoms | Tells your clinician whether an exam or test is needed |
| Your cancer and medication history | Changes the risk-benefit conversation |
Could this be something other than menopause dryness?
Yes — and this is the question that keeps women from spinning their wheels. Irritant or allergic reactions, vaginal infections or UTIs, vulvar skin conditions, pelvic-floor tension, Sjögren’s disease, diabetes, certain medications, and lack of arousal can all mimic or overlap with GSM.
Burning or itching with discharge or odor
This can point to an infection like a yeast infection or bacterial vaginosis, which needs testing — not a guess. Not every itch is yeast, and treating the wrong thing wastes time.
Outside itching, tearing, whitening, or skin changes
Vulvar skin conditions can travel alongside menopause dryness. One important example is lichen sclerosus, a skin condition that causes itching, whitening, and fragile skin. It’s treated primarily with a strong prescription topical steroid — estrogen doesn’t treat the lichen sclerosus itself. This usually needs a look in person.
Tightness or pain right at the opening
Dryness can coexist with pelvic-floor tension — muscles that guard and tighten. More estrogen isn’t automatically the whole answer, and pelvic-floor physical therapy may be part of the plan.
Deep pelvic pain
Deep pain is not the same as surface dryness and deserves its own evaluation.
Urgency, frequency, burning, or repeat UTI-like symptoms
GSM can include urinary symptoms. But an active infection shouldn’t be diagnosed off an online list. Guidelines support discussing low-dose vaginal estrogen to help prevent recurrent UTIs in appropriate women after menopause — but it doesn’t replace testing and treating a suspected active infection.
Dry eyes and dry mouth too?
When dryness shows up across your body, it can point to Sjögren’s disease, an autoimmune condition that dries out the body’s moisture-making glands. Women who have Sjögren’s report vaginal dryness about 2 to 3 times more often than women the same age without it. Dry eyes and dry mouth alongside genital dryness are a reason to ask about a broader evaluation.
Irritants, medications, and low arousal
Perfumed washes, wipes, douching, harsh detergents, and some pads can irritate. So can certain medicines — allergy and cold medicines (antihistamines), some antidepressants, and the breast-cancer therapies tamoxifen and aromatase inhibitors can all contribute. Insufficient arousal can also reduce lubrication during sex, and it can coexist with GSM. None of this is a failing on your part. It’s just worth checking.
Symptom-pattern matrix
| Symptom pattern | What it raises for discussion | Best setting |
|---|---|---|
| Dryness alone, stable, GSM already diagnosed | Timing, route, formulation, local-treatment options | Online or your current prescriber may be fine |
| Burning right after applying a product | Product irritation, a reaction, infection, or another cause | Prescriber review; exam if it persists |
| Discharge or odor | Vaginitis or another cause that needs testing | In-person assessment |
| Outside skin change, tearing, or persistent itching | A vulvar skin condition (e.g., lichen sclerosus) or fragile tissue | In-person exam |
| Tightness or entry pain | Dryness plus a pelvic-floor component | Exam; possible pelvic-floor referral |
| Urinary burning, urgency, or frequency | GSM, UTI, or another urinary cause | Urine testing or in-person review |
| New or unexplained postmenopausal bleeding | Needs evaluation — not assumed to be dryness | Prompt clinical assessment |
This matrix helps you organize a conversation. It does not identify the cause of any one symptom.
When should I stop troubleshooting online and get examined?
Some patterns need eyes and hands, not a bigger dose. New or unexplained bleeding after menopause, repeated bleeding after sex, unusual discharge or odor, visible sores or skin changes, or severe or worsening pain should be evaluated in person rather than blamed on dryness.
Book a prompt in-person assessment for any of these:
- ⚠
New or unexplained bleeding after menopause
Expected withdrawal bleeding on a prescribed sequential HRT regimen is a different, planned pattern, and light spotting can happen in the first months of HRT. But heavy, persistent, or recurrent bleeding — or bleeding outside your regimen's expected pattern — needs review. ACOG updated its guidance on evaluating postmenopausal bleeding in April 2026.
- ⚠
Repeated bleeding after sex
- ⚠
Unusual discharge or odor
- ⚠
Visible sores, lesions, whitening, thickening, or unexplained skin changes
- ⚠
Pelvic or vaginal pain that's severe, worsening, or unexplained
- ⚠
Symptoms that get worse during treatment
A good online service will tell you when it can’t help remotely.If your symptoms need a swab, a urine test, or an exam, a responsible telehealth clinician should say so and route you to in-person care — not keep adjusting hormones from a distance. That’s a feature, not a failure.
A safety line worth repeating
Do not increase your systemic or vaginal hormone dose just to “test” whether bleeding, discharge, skin changes, or serious pain goes away. Get it looked at.
What treatments can help when HRT alone isn’t enough?
The right next option depends on the cause and your history — there’s no single answer for everyone. Evidence-based options a clinician may discuss include vaginal moisturizers and lubricants, FDA-approved low-dose vaginal estrogen, vaginal prasterone, oral ospemifene, and pelvic-floor therapy. Energy-based “vaginal rejuvenation” lasers are not FDA-approved for menopause symptoms.
| Option to discuss | What it’s meant to help | Important limit or question |
|---|---|---|
| Vaginal lubricant | Friction during sex | Temporary; doesn't treat the underlying cause |
| Vaginal moisturizer | Regular, non-prescription comfort | May not be enough for moderate or severe symptoms |
| FDA-approved low-dose vaginal estrogen | Local GSM symptoms | Needs an individual review; product and route matter |
| Vaginal prasterone (Intrarosa) | Painful sex linked to menopause | Not right for every history; see the cancer note below |
| Oral ospemifene (Osphena) | Certain vulvovaginal symptoms | It's systemic and carries a boxed warning; needs review |
| Pelvic-floor physical therapy | Muscle tension, tightness, entry pain | Doesn't replace treating the tissue or an infection |
| Systemic HRT adjustment | Broader menopause symptoms still uncontrolled | Dryness alone doesn't prove you need a higher systemic dose |
| Energy-based laser or radiofrequency | Marketed for vaginal symptoms | Not FDA-approved for menopause symptoms; ACOG warns of burns, scarring, and pain |
Prasterone (Intrarosa)
A vaginal insert of DHEA — a hormone your body converts into small amounts of estrogen and androgen right in the tissue. FDA-approved for moderate-to-severe painful sex due to menopause. Because the body makes estrogen from it locally, it isn’t a cleanly “estrogen-free” choice, and there are specific cautions for anyone with a breast-cancer history.
An oral pill in a class called SERMs. FDA-approved for painful sex and vaginal dryness from menopause. Unlike local products, it’s systemic, and it carries a boxed warning (including risks related to the uterine lining and blood clots), so it needs an individual review.
About lasers
You’ll see clinics market “vaginal rejuvenation.” Be cautious. The FDA has not approved these energy devices to treat menopausal vaginal symptoms, and ACOG has flagged reports of burns, scarring, and lasting pain. Testimonials aren’t proof of safety or effectiveness here.
FDA-approved vs compounded, one more time
If a compounded hormone comes up, ask why it’s being suggested over an FDA-approved option, what isn’t established about it, and which approved alternatives were considered. We never treat a compounded product as interchangeable with an FDA-approved one.
What changes if I’ve had breast cancer, or take tamoxifen or an aromatase inhibitor?
If you have a history of estrogen-sensitive breast cancer, the general approach is non-hormonal options first, with any hormone decision made alongside your care team. ACOG says non-hormonal methods are first-line; low-dose vaginal estrogen may be considered after an individual risk-benefit discussion, with shared decision-making that includes your oncologist when an aromatase inhibitor is involved. There’s no single online yes-or-no here.
Your history changes the whole conversation — it belongs with your clinicians.
What to bring so that conversation is a good one:
- •Your type of cancer
- •Whether you take (or took) tamoxifen or an aromatase inhibitor
- •Your oncology contact
- •Non-hormonal treatments you've already tried
- •How much the symptoms affect your life
Vaginal prasteronehas not been studied in women with a history of breast cancer, and its label cautions because estrogen is one of the hormones the body makes from it. ACOG notes vaginal DHEA may be discussed when vaginal estrogen isn’t an option.
Ospemifene’s U.S. label says it should not be used in women with known, suspected, or past breast cancer, while ACOG says it may be considered case by case, noting long-term safety data are limited. These are specialist-led decisions, not self-serve choices.
Do I need an online HRT review or an in-person exam?
Online care can be a reasonable starting point when your menopause diagnosis is already established, your symptoms are stable, and you have no red flags. An in-person exam should come first when there’s new or unexplained bleeding, unusual discharge, sores or skin changes, severe or worsening pain, or an uncertain diagnosis.
An online review may be reasonable when:
- ✓You already have a menopause/HRT diagnosis
- ✓Your symptoms are steady
- ✓You have no new or unexplained bleeding
- ✓You have no unusual discharge, odor, sore, or new skin change
- ✓Your main question is route, product, schedule, timing, or a medication check-in
- ✓The service can arrange local testing or refer you in person when needed
An in-person exam should come first when:
- ⚠There's new or unexplained bleeding
- ⚠Repeated bleeding after sex
- ⚠Unusual discharge or odor
- ⚠Visible sores or skin changes
- ⚠Severe or worsening pain
- ⚠An uncertain diagnosis
- ⚠Symptoms that persist after a proper treatment trial
The most honest first move for most women:ask the clinician already managing your HRT whether this needs a medication review, targeted local treatment, or an exam. If you already have an HRT prescriber, that’s often a quick conversation — no new relationship required.
Looking for a menopause-focused telehealth provider?
If you don’t have an HRT prescriber or want a menopause specialist: Midi Health works in all 50 states, prescribes FDA-approved options, and is in-network with many PPO plans. Self-pay is $250 for a first visit and $150 for follow-ups. One access note: Midi can’t treat Medicaid or Medi-Cal patients, and while Medicare beneficiaries can self-pay, Midi doesn’t bill Medicare.
The HRT Index earns a commission if you start care with Midi; it never changes our safety flags or what we tell you to verify. Affiliate disclosure
What to ask your clinician (and what to bring)
Walk in with the exact medication name, route, dose, start date, missed-dose history, a symptom timeline, and which symptoms did or didn’t improve. Your goal is to leave with a clear working diagnosis, a plan, a timeline, and a specific reason to follow up.
Ten questions you can copy and paste
- 1
Does my symptom pattern still fit GSM, or should another cause be ruled out?
- 2
Is my current treatment systemic, local, or both?
- 3
Has it had enough time to judge fairly?
- 4
Am I using this exact product the way it's meant to be used?
- 5
Could irritation, infection, a skin condition, or pelvic-floor tension be part of this?
- 6
Would an FDA-approved local option, or a different form, be right for me?
- 7
Does my uterus, bleeding history, cancer history, or current medication change my options?
- 8
What improvement should I expect, and by what date?
- 9
Which symptoms should make me contact you sooner?
- 10
What's the plan if I'm not meaningfully better at the follow-up?
What to bring
Your product box or a clear photo, your prescription instructions, start and change dates, missed-dose history, a symptom timeline, a list of the non-prescription products you use, your bleeding and discharge history, any urine-test history, and your cancer and medication history.
How The HRT Index verified this guidance
Who made this. By The HRT Index Editorial Team. This is editorial research for education. It was notmedically reviewed by a clinician, and it doesn’t diagnose you, decide your eligibility, or tell you to start, stop, or change a medication.
How we did it.Medical and regulatory statements were checked against current guidelines (the 2025 AUA/SUFU/AUGS GSM guideline, ACOG, The Menopause Society), the FDA’s February 2026 labeling actions, and current prescribing information on DailyMed. Patient-facing explanations were checked against the NHS, Mayo Clinic, and MedlinePlus. Our care-routing suggestions are labeled as discussion aids, not diagnoses.
How we review providers. When we compare telehealth providers, we use five pillars, always in this order: clinical legitimacy, care quality, medication fit, price transparency, and access — you can read the full method on our methodology page. This symptom page does not assign any provider a numeric score.
Why this page exists.Because women whose HRT fixed some symptoms but not vaginal or urinary ones deserve a clear bridge between “keep waiting,” “ask about a different route,” and “get examined” — instead of a shrug and a “give it time.” If we get something wrong, we fix it and note what changed and when on our corrections page.
Frequently asked questions: vaginal dryness not improving on HRT
Can an estrogen patch help hot flashes but not vaginal dryness?
Yes. Systemic HRT like a patch can ease whole-body symptoms while local vaginal or vulvar symptoms persist. That's why a clinician may add targeted local treatment rather than just raising your dose.
How long does vaginal estrogen take to work?
Some improvement can start within a few weeks, but full benefit can take up to three months. Ask for a defined review date, and get seen sooner for worsening symptoms or red flags.
What counts as a "fair trial" of vaginal estrogen?
Using the exact prescribed product and schedule through your planned review point — often up to three months — unless symptoms get worse or a red flag appears sooner. A different product may have a different schedule.
Can I use vaginal estrogen with an HRT patch or pill?
Often, yes. Clinicians frequently prescribe low-dose local vaginal estrogen alongside systemic HRT when local symptoms persist. Your history and the exact product still need a prescriber's review — and Duavee is an exception, since its label says not to add estrogens.
Does vaginal dryness mean my estrogen dose is too low?
Not by itself. Route, timing, how consistently you use it, whether your other symptoms improved, local-treatment options, and other causes all matter more than the dose number.
Why does vaginal estrogen cream burn or itch?
It can be the product, an ingredient reaction, an infection, outside irritation, or another condition. Burning that persists or worsens should go to your prescriber — not be treated as a sign you need more estrogen.
Is vaginal itching always a yeast infection?
No. Irritation, GSM, skin conditions, and other kinds of vaginitis can look alike. Testing may be needed, so don't assume — especially if treatments aren't working.
Can vaginal estrogen help with recurrent UTIs?
Guidelines support discussing low-dose vaginal estrogen to help prevent recurrent UTIs in appropriate women after menopause. It doesn't replace testing and treating a suspected active infection.
Can I use a vaginal moisturizer or lubricant with vaginal estrogen?
Often, yes. Lubricants reduce friction during sex; moisturizers give regular comfort. They can be used alongside prescription care — but follow the product label and ask your prescriber about timing or ingredient compatibility.
Do I need progesterone with vaginal estrogen?
It depends on the product. Low-dose local vaginal estrogen generally doesn't require added progestogen, but a systemic ring like Femring generally does if you have a uterus — and it doesn't replace the progestogen plan your systemic HRT already requires. Confirm exactly which product you have.
Are Estring and Femring the same type of treatment?
No. Estring is a local, low-dose vaginal ring; Femring delivers systemic estrogen. They're used for different reasons and carry different considerations — always check which one you have.
Is vaginal laser FDA-approved for menopause dryness?
No. Energy-based devices are not FDA-approved to treat menopausal vaginal symptoms, and ACOG has warned about burns, scarring, and pain. Treat marketing claims with caution.
Is bleeding after sex just vaginal dryness?
Fragile tissue can contribute, but repeated bleeding after sex — and any new or unexplained bleeding after menopause — should be evaluated. Expected withdrawal bleeding on a sequential HRT regimen is a separate, planned pattern.
Still not sure which HRT path is right for you? Take our free 90-second matching quiz. It can also flag when an in-person clinician is the safer place to start.
Take Find My HRT Path →Sources
- •American Urological Association / SUFU / AUGS — Genitourinary Syndrome of Menopause (GSM) Guideline (2025). auajournals.org
- •ACOG — Treatment of Urogenital Symptoms in Individuals With a History of Estrogen-Dependent Breast Cancer (Clinical Consensus, 2021); Compounded Bioidentical Menopausal Hormone Therapy (2023); updated guidance on evaluating postmenopausal bleeding (April 2026); Vaginal Laser Therapy: What Is It?; Vaginitis FAQ. acog.org
- •The Menopause Society — GSM and genitourinary patient education. menopause.org
- •U.S. FDA — FDA Approves Labeling Changes for Menopausal Hormone Therapy Products (February 12, 2026). fda.gov
- •DailyMed (U.S. National Library of Medicine) — current prescribing information for Estring, Femring, Duavee, Intrarosa (prasterone), and Osphena (ospemifene). dailymed.nlm.nih.gov
- •JAMA Network Open (2025) — Medicare cohort on vaginal-estrogen use among women with a GSM-related diagnosis.
- •Johns Hopkins Sjögren's Center — vaginal dryness in Sjögren's disease. hopkinssjogrens.org
- •NHS — Vaginal dryness; Vaginal oestrogen; Postmenopausal bleeding; Lichen sclerosus. nhs.uk
- •Mayo Clinic — Vaginal dryness after menopause: How to treat it? mayoclinic.org
Affiliate disclosure · Medical review policy · Our methodology